Baxter International Inc. announced that the company has submitted a biologics license application (BLA) to the FDA for the approval...
Fuzeon is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected patients who have received treatment with and failed on regimens containing at least one medicinal product from each of the following antiretroviral classes: protease inhibitors, non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors, or who have intolerance to previous antiretroviral regimens (see section 5.1). In deciding on a new regimen for patients who have failed an antiretroviral regimen, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different medicinal products. Where available, resistance testing may be appropriate (see sections 4.4 and 5.1).
Gilead Sciences, Inc. presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes (PRO) from the Phase II/III CAPELLA trial
BD (Becton, Dickinson and Company) released findings from a survey conducted by The Harris Poll, between Nov. 14-16, 2022, among 872 U.S. women ages 18 to 64 years old, that indicate a significant gap in women's knowledge about the primary causes of cervical cancer as well as the most effective means of prevention.
Atara Biotherapeutics, Inc. announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel or Ebvallo)
Atara Biotherapeutics announced that the Marketing Authorization Application (MAA) for tab-cel (tabelecleucel) has been fully validated by the European Medicines Agency (EMA).
South Korea�s Ministry of Food and Drug Safety (MFDS) has upheld its conditional approval of Olita Tab (olmutinib) (also known...
ObsEva SA announced that the Phase III clinical trial results from its European confirmatory study of nolasiban (IMPLANT 4) in...
This review will explore quantitative eye and pupil tracking as a potential noninvasive, time-effective, and less technically demanding alternative to current diagnostic tests of MG.